publicly traded companies glp-1 receptor agonist manufacturers Market Size and Share GLP-1 Receptor Agonist Market Size

For example, liraglutide might reduce the occurrence rate of myocardial infarction in high-risk T2DM patients and enhance the clinical outcomes of myocardial infarction (28)

Demand for such drugs is likely to continue to be strong in the future due to rising rates of obesity and interlinked chronic diseases

The duration of follow-up varied from 5 weeks to over 3 years, once again demonstrating both short-term and long-term benefits of GLP-1RAs in managing albuminuria and improving kidney outcomes

Therefore, GLP-1RAs and GIP-RAs hold promise to be potential treatments for a wide variety of diseases

Crohn's disease is a chronic inflammatory bowel disease (IBD) characterized by transmural inflammation that can affect any portion of the gastrointestinal tract from mouth to anus, though it most commonly involves the terminal ileum and colon

During a meeting with investors in May, Lupin executives said they are developing both injectable and tablet forms of semaglutide for sale in India and South Africa in 2026